A6141116- Early Treatment with Eplerenone for Acute MI
Research type
Research Study
Full title
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF EARLY TREATMENT WITH EPLERENONE IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION.
IRAS ID
68665
Contact name
Gregory Lip
Contact email
Sponsor organisation
Pfizer Inc.
Eudract number
2010-019844-38
Clinicaltrials.gov Identifier
Research summary
Eplerenone has been demonstrated to have effects on the heart muscle. It has been shown to improve survival when eplerenone treatment is commenced within three to fourteen days following an acute myocardial infarction involving other heart complications. This study seeks to investigate the effects of initiating eplerenone treatment within 24 hours of onsent of acute myocardial infarction to find out if this shows an improvement in survival.Suitable subjects will be enrolled into two arms; one will receive placebo and one will receive eplerenone. All subjects will continue to receive standard care alongside study treatments.
REC name
West of Scotland REC 1
REC reference
10/S0703/75
Date of REC Opinion
1 Feb 2011
REC opinion
Further Information Favourable Opinion